

## **RXi gets \$300K SBIR grant for retinal cancer therapy**

Mass High Tech: The Journal of New England Technology

Westborough-based RXi Pharmaceuticals Corporation (OTC: RXII) has been awarded a \$300,000 Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI) to develop therapeutic RNAi compounds that can be self-delivered to more effectively treat a retinal cancer commonly affecting children.

**Source URL (retrieved on 03/06/2015 - 5:42pm):**

<http://www.mdtmag.com/news/2012/10/rxi-gets-300k-sbir-grant-retinal-cancer-therapy>